Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CRISPR-associated endonuclease Cas9 (Cas9) is an RNA-guided DNA endonuclease derived from the Type II CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) adaptive immune system of bacteria, most notably Streptococcus pyogenes. In its native bacterial context, Cas9 functions to defend against invading bacteriophages and plasmids by unwinding foreign DNA and introducing site-specific double-strand breaks (DSBs) guided by a dual-RNA complex (crRNA and tracrRNA). In biotechnology and medicine, this system has been engineered into a single-guide RNA (sgRNA) and Cas9 complex, enabling highly precise, programmable genome editing in eukaryotic cells. Upon binding to a target genomic locus adjacent to a protospacer adjacent motif (PAM), Cas9 utilizes its RuvC and HNH nuclease domains to cleave both strands of DNA. The resulting DSBs are repaired by the host cell's endogenous DNA repair pathways, such as non-homologous end joining (NHEJ) or homology-directed repair (HDR), allowing for gene knockout, gene correction, or gene insertion. Cas9-based therapeutics, such as the FDA-approved exagamglogene autotemcel (Casgevy), are being actively developed to treat a wide range of human diseases, including genetic disorders (e.g., sickle cell disease, beta-thalassemia, transthyretin amyloidosis), cancers, and chronic viral infections. However, therapeutic translation faces challenges such as off-target editing, potential genotoxicity, and host immunogenicity against the bacterial Cas9 protein.
RNA-guided double-stranded DNA cleavage to facilitate gene knockout, correction, or insertion via cellular repair pathways.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CRISPR-associated endonuclease Cas9 (Cas9).